MUSTANG BIO, INC.
Datakwaliteit: 83%
MBIO
Nasdaq
Manufacturing
Chemicals
€ 0,74
▼
€ 0,01
(-0,93%)
Marktkapitalisatie: 5,63 M
Prijs
€ 0,74
Marktkapitalisatie
5,63 M
Dagbereik
€ 0,74 — € 0,75
52-Weeksbereik
€ 0,53 — € 7,00
Volume
9.044
Openen € 0,74
50D / 200D Gem.
€ 0,89
16,56% below
50D / 200D Gem.
€ 1,33
44,18% below
Quick Summary
Belangrijkste Punten
Negative free cash flow of -5,26 M
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
-30,34%
Boven sectorgemiddelde (-53,41%)
ROIC-29,64%
Net MarginN/A
Op. MarginN/A
Veiligheid
Debt / Equity
N/A
Current Ratio2,05
Interest CoverageN/A
Waardering
PE (TTM)
-2,93
Onder sectorgemiddelde (-1,48)
P/B Ratio0,58
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -2,9 | -1,5 |
| P/B | 0,6 | 1,6 |
| ROE % | -30,3 | -53,4 |
| Net Margin % | — | -41,5 |
| Rev Growth 5Y % | — | 1,8 |
| D/E | — | 0,3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -1,92 M |
| ROE | -30,34% | ROA | -11,86% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -5,26 M |
| ROIC | -29,64% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 2,05 |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | 9,92 M | Tangible Book Value | 9,77 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -2,93 | Forward P/E | N/A |
| P/B Ratio | 0,58 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -93,49% | ||
| Market Cap | 5,63 M | Enterprise Value | -13,35 M |
| Per Share | |||
| EPS (Diluted TTM) | -0,39 | Revenue / Share | N/A |
| FCF / Share | -0,69 | OCF / Share | -0,69 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 274,02% |
| SBC-Adj. FCF | -5,41 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -1,92 M | -15,75 M | -51,60 M | -77,53 M | -66,37 M |
| EPS (Diluted) | -0,39 | -38,57 | -6,00 | -0,75 | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -2,43 M | -16,25 M | -49,26 M | -76,16 M | -66,72 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | — | — | — | — | — |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | — | — | — | — |
| Interest Expense | — | 5.000,0 | 4,11 M | 3,36 M | — |
| Income Tax | 27.000,0 | — | — | — | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 17,59 M | 9,31 M | 17,74 M | 92,42 M | 125,17 M |
| Total Liabilities | 8,06 M | 13,18 M | 17,62 M | 46,15 M | 12,77 M |
| Shareholders' Equity | 9,53 M | -3,87 M | 123.000,0 | 46,27 M | 112,40 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 17,27 M | 6,84 M | 6,23 M | 75,66 M | 109,62 M |
| Current Assets | 17,59 M | 8,61 M | 11,35 M | 78,85 M | 111,71 M |
| Current Liabilities | 7,91 M | 12,61 M | 15,37 M | 15,11 M | 10,82 M |
{"event":"ticker_viewed","properties":{"ticker":"MBIO","listing_kind":"stock","pathname":"/stocks/mbio","exchange":"Nasdaq","country":"US"}}